Advertisement

Advertisement

ZNTL Stock Latest News

Analyst Reiterates Buy on Azenosertib’s Ovarian Cancer Prospects With Unchanged $10 Price Target

RatingsAnalyst Reiterates Buy on Azenosertib’s Ovarian Cancer Prospects With Unchanged $10 Price Target

Zentalis announces first OS data from DENALI part 1b study

PremiumThe Fly

Zentalis announces first OS data from DENALI part 1b study

20h ago

Zentalis assumed at Outperform from Market Perform at Leerink

PremiumThe Fly

Zentalis assumed at Outperform from Market Perform at Leerink

14d ago

Zentalis initiated with an Outperform at William Blair

PremiumThe Fly

Zentalis initiated with an Outperform at William Blair

1M ago

Zentalis announecs common stock offering, no amount given

PremiumThe Fly

Zentalis announecs common stock offering, no amount given

2M ago

Zentalis 23M share Spot Secondary priced at $3.50

PremiumThe FlyZentalis 23M share Spot Secondary priced at $3.50

2M ago

Zentalis Pharmaceuticals Announces Major Common Stock Offering

Company Announcements

Zentalis Pharmaceuticals Announces Major Common Stock Offering

2M ago

Zentalis price target raised to $5 from $4 at Morgan Stanley

The Fly

Zentalis price target raised to $5 from $4 at Morgan Stanley

2M ago

Regulatory Clarity and Trial Progress Support Azenosertib Outlook; Buy Rating Reiterated with Unchanged $10 Price Target

PremiumRatings

Regulatory Clarity and Trial Progress Support Azenosertib Outlook; Buy Rating Reiterated with Unchanged $10 Price Target

2M ago

Zentalis reports Q2 EPS (59c), consensus (48c)

PremiumThe Fly

Zentalis reports Q2 EPS (59c), consensus (48c)

2M ago

Zentalis Highlights Q2 Results and Azenosertib Progress

PremiumCompany Announcements

Zentalis Highlights Q2 Results and Azenosertib Progress

2M ago

Zentalis initiated with a Buy at Rodman & Renshaw

PremiumThe Fly

Zentalis initiated with a Buy at Rodman & Renshaw

3M ago

Zentalis initiated with an Outperform at Mizuho

PremiumThe FlyZentalis initiated with an Outperform at Mizuho

3M ago

Zentalis Shareholders Back Directors, Auditors and Executive Pay

Company Announcements

Zentalis Shareholders Back Directors, Auditors and Executive Pay

4M ago

Zentalis assumed with an Outperform at Oppenheimer

The Fly

Zentalis assumed with an Outperform at Oppenheimer

4M ago

Zentalis Pharmaceuticals Expands Board, Appoints New Director

PremiumCompany Announcements

Zentalis Pharmaceuticals Expands Board, Appoints New Director

5M ago

Analyst Reiterates Buy on Zentalis as New MUIR Data Bolster Azenosertib Outlook; $10 Price Target Unchanged

PremiumRatings

Analyst Reiterates Buy on Zentalis as New MUIR Data Bolster Azenosertib Outlook; $10 Price Target Unchanged

5M ago

Zentalis Highlights Promising Azenosertib Data in Ovarian Cancer

PremiumCompany Announcements

Zentalis Highlights Promising Azenosertib Data in Ovarian Cancer

5M ago

Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts

PremiumRatings

Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts

5M ago

Zentalis reports Q1 EPS (50c), consensus (52c)

PremiumThe FlyZentalis reports Q1 EPS (50c), consensus (52c)

5M ago

Zentalis Advances Azenosertib with New Trial Updates

Company Announcements

Zentalis Advances Azenosertib with New Trial Updates

5M ago

ZNTL Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Pre-Earnings

ZNTL Earnings Report this Week: Is It a Buy, Ahead of Earnings?

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >